Dakota Wealth Management Decreases Position in Zoetis Inc. $ZTS

Dakota Wealth Management lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 9.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,558 shares of the company’s stock after selling 6,063 shares during the quarter. Dakota Wealth Management’s holdings in Zoetis were worth $8,129,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ZTS. Norges Bank purchased a new stake in shares of Zoetis during the second quarter worth $809,491,000. Diamond Hill Capital Management Inc. purchased a new stake in Zoetis during the 3rd quarter valued at about $394,010,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Zoetis by 113.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after acquiring an additional 1,995,491 shares during the last quarter. Corient Private Wealth LLC lifted its stake in Zoetis by 85.9% in the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after purchasing an additional 1,191,840 shares in the last quarter. Finally, Impax Asset Management Group plc boosted its holdings in shares of Zoetis by 362.6% during the 2nd quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock worth $182,705,000 after purchasing an additional 922,589 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ZTS. Stifel Nicolaus dropped their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. UBS Group set a $136.00 price target on shares of Zoetis in a research note on Thursday, January 29th. Morgan Stanley set a $160.00 price objective on Zoetis in a report on Thursday, December 18th. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Finally, KeyCorp started coverage on Zoetis in a research report on Thursday, November 20th. They issued a “sector weight” rating on the stock. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

Shares of Zoetis stock opened at $125.77 on Tuesday. The business has a 50-day moving average of $125.50 and a 200 day moving average of $134.48. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.00. The stock has a market capitalization of $53.09 billion, a price-to-earnings ratio of 20.89, a price-to-earnings-growth ratio of 1.97 and a beta of 0.96. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period in the prior year, the firm earned $1.40 earnings per share. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.